A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.
Affiliation
CRC Department of Medical Oncology, University of Manchester, Christie Hospital and Wythenshawe Hospital, UK.Issue Date
1996-08
Metadata
Show full item recordAbstract
A phase I study to determine the maximum tolerated dose and toxicity of gemcitabine when given as a 24 h infusion to patients with inoperable non-small-cell lung cancer (NSCLC). A total of 24 patients with unresectable stage IIIa-IV NSCLC were entered into the study. Gemcitabine was administered as a 24 h infusion on days 0, 7 and 14. Courses of therapy were repeated every 28 days. There were 16 males and 8 females with a median age of 51 years (range 40-73 years). The WHO performance score was 1 (21 patients) or 2 (3 patients). The TNM stage was IIIa (6), IIIb (10) and IV (8). Three patients were entered at each dose level with six at the maximum tolerated dose (MTD). Dose levels were 10, 20, 40, 80, 120, 180 and 210 mg m-2. The MTD was 180 mg m-2 and dose-limiting toxicity was neutropenia and lethargy. Partial response was observed in five (21%) patients (95% CI 7-42%) lasting 10, 14, 18, 47 and 51 + weeks. The maximum tolerated dose of gemcitabine given as a 24 h infusion was 180 mg m-2.Citation
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. 1996, 74 (3):460-2 Br. J. CancerJournal
British Journal of CancerPubMed ID
8695365Type
ArticleLanguage
enISSN
0007-0920Collections
Related articles
- Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
- Authors: Levitt ML, Kassem B, Gooding WE, Miketic LM, Landreneau RJ, Ferson PF, Keenan R, Yousem SA, Lindberg CA, Trenn MR, Ponas RS, Tarasoff P, Sabatine JM, Friberg D, Whiteside TL
- Issue date: 2004 Mar
- Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
- Authors: Zwitter M, Kovac V, Smrdel U, Strojan P
- Issue date: 2006 Sep
- Incidental surgical findings of a phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with unresectable non-small cell lung cancer.
- Authors: Cesario A, Margaritora S, Trodella L, Valente S, Corbo GM, Macis G, Galetta D, d'Angelillo RM, Porziella V, Ramella S, Mangiacotti MG, Granone P
- Issue date: 2002 Aug
- Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
- Authors: Franciosi V, Barbieri R, Aitini E, Vasini G, Cacciani GC, Capra R, Camisa R, Cascinu S
- Issue date: 2003 Jul
- Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
- Authors: Athanasiadis A, Roussos G, Papakostoulis T, Athanasiadou DC, Stathopoulos GP
- Issue date: 2005 Dec